| Aktie | Ticker | Breite | GCS | 2026/Q1 | 2025/Q4 | 2025/Q3 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| 141.410.507 $ | -9.649.994 $ | -18,8 % | 8 | 151.060.501 $ | -54.438.470 $ | -13,9 % | 7 | 212.452.986 $ | +130.316.101 $ | +46,1 % | 9 | ||||
| LENZ Therapeutics, Inc. | LENZ | → 0 | Neutral | 24.310.525 $ | -18.199.683 $ | -42,8 % | 1 | 42.510.208 $ | -81.247.635 $ | -65,7 % | 1 | 123.757.843 $ | +123.757.843 $ | 1 | |
| Monte Rosa Therapeutics, Inc. | GLUE | → 0 | Schwach | 52.323.831 $ | -16.396.701 $ | -23,9 % | 1 | 68.720.532 $ | +26.832.380 $ | +64,1 % | 1 | 41.888.152 $ | +16.393.474 $ | +64,3 % | 1 |
| Century Therapeutics, Inc. | IPSC | → 0 | Neutral | 27.495.406 $ | +27.495.406 $ | 1 | |||||||||
| Jade Biosciences, Inc. | JBIO | → 0 | Schwach | 21.437.771 $ | -2.105.632 $ | -8,9 % | 1 | 23.543.403 $ | +10.375.576 $ | +78,8 % | 1 | 13.167.827 $ | -2.075.115 $ | -13,6 % | 1 |
| CRISPR Therapeutics AG | CRSP | → 0 | Neutral | 7.079.891 $ | -724.807 $ | -9,3 % | 1 | 7.804.698 $ | -1.841.039 $ | -19,1 % | 1 | 9.645.737 $ | -14.604.124 $ | -60,2 % | 1 |
| Skye Bioscience, Inc. | SKYE | → 0 | 1.233.935 $ | -271.241 $ | -18,0 % | 1 | 1.505.176 $ | -6.385.101 $ | -80,9 % | 1 | 7.890.277 $ | -501.926 $ | -6,0 % | 1 | |
| Contineum Therapeutics, Inc. | CTNM | → 0 | Schwach | 7.086.722 $ | +884.484 $ | +14,3 % | 1 | 6.202.238 $ | -173.641 $ | -2,7 % | 1 | 6.375.879 $ | +4.221.646 $ | +196,0 % | 1 |
| Repare Therapeutics Inc. | → 0 | 4.658.116 $ | +979.263 $ | +26,6 % | 1 | ||||||||||
| Tempest Therapeutics, Inc. | TPST | → 0 | Sehr schwach | 442.426 $ | -331.820 $ | -42,9 % | 1 | 774.246 $ | -1.999.010 $ | -72,1 % | 1 | 2.773.256 $ | +938.806 $ | +51,2 % | 1 |
| Adverum Biotechnologies, Inc. | ADVM | → 0 | 2.295.899 $ | +1.206.234 $ | +110,7 % | 1 | |||||||||
| 141.410.507 $ | -9.649.994 $ | -18,8 % | 8 | 151.060.501 $ | -54.438.470 $ | -13,9 % | 7 | 212.452.986 $ | +130.316.101 $ | +46,1 % | 9 | ||||